← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Battelle Memorial Institu
Columbus, OH
$67,383,603
Total funding
3
Grants
Funding over time
peak $23.9M · FY2016–24$25M$18.8M$12.5M$6.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$67,383,603 · 3
By mechanism
N01$67,383,603 · 3
Investigators at Battelle Memorial Institu
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Largest grants
Conduct of studies to evaluate the toxic and carcinogenic potential of naturally occurring asbestos and related mineral fibers in laboratory animals$5,393,328
N01 · FY2021 · ES
Conduct of studies to evaluate the toxic and carcinogenic potential of naturally occurring asbestos and related mineral fibers in laboratory animals$5,330,513
N01 · FY2023 · ES
Conduct of studies to evaluate the toxic potential of C9-alkylbenzenes in laboratory animals$3,984,892
N01 · FY2023 · ES
Conduct of studies to evaluate the toxic potential of C9-alkylbenzenes in laboratory animals$3,931,148
N01 · FY2021 · ES
Conduct of studies to evaluate the toxic and carcinogenic potential of naturally occurring asbestos and related mineral fibers in laboratory animals$3,709,608
N01 · FY2022 · ES
Conduct of studies to evaluate the subchronic and developmental neurotoxicity of isopropylated phenol phosphate (IPP) in rats (after perinatal exposure)$3,344,706
N01 · FY2021 · ES
Conduct of studies to evaluate the toxic potential of C9-alkylbenzenes in laboratory animals$2,636,818
N01 · FY2022 · ES
Support for the Conduct of Studies to Evaluate the Impact of Genetic Background and Potential Treatments of SARS-CoV-2 Induced Pneumonia$2,516,993
N01 · FY2021 · ES
Conduct of Studies to Evaluate the Cardiovascular Toxicity of an HIV Tricombo Therapy (ABC/DTG/3TC) ing Sprague Dawley Rats (F0 Dosed by Oral Gavage; F1 Exposed Perinatally)$2,164,226
N01 · FY2023 · ES
Conduct of studies to evaluate the subchronic and developmental neurotoxicity of isopropylated phenol phosphate (IPP) and triphenyl phosphate (TPHP)in rats (after perinatal exposure)$1,985,021
N01 · FY2023 · ES
Support of the Research Effort to Evaluate the Cardiotoxic Potential of Multiple Test Agents in Rats$1,932,991
N01 · FY2023 · ES
Conduct of studies to evaluate the subchronic and developmental neurotoxicity of triphenyl phosphate (TPHP) in rats (after perinatal exposure)$1,912,683
N01 · FY2022 · ES
Evaluation and use of 2D and 3D HepaRG cells to screen for chemical toxicity$1,745,926
N01 · FY2023 · ES
Establish and Characterize an Air Liquid Interface In Vitro Exposure System$1,490,016
N01 · FY2023 · ES
Conduct of Studies to Evaluate the Cardiovascular Toxicity of an HIV Tricombo Therapy (ABC/DTG/3TC) ing Sprague Dawley Rats (F0 Dosed by Oral Gavage; F1 Exposed Perinatally)$1,449,000
N01 · FY2021 · ES
Evaluation of multiple test agents for functional cardiovascular changes in rats$1,423,206
N01 · FY2023 · ES
Establish and Characterize an Air Liquid Interface In Vitro Exposure System$1,397,365
N01 · FY2021 · ES
Conduct of studies to evaluate the subchronic and developmental neurotoxicity of isopropylated phenol phosphate (IPP) in rats (after perinatal exposure)$1,312,001
N01 · FY2022 · ES
Evaluation of Physiological Monitoring in Tocivology using 2-Ethyltoluene as a case study$1,310,781
N01 · FY2024 · ES
Establish and Characterize an Air Liquid Interface In Vitro Exposure System$1,244,142
N01 · FY2022 · ES